 SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 GLOBE NEWSWIRE -- Alector, Inc. Nasdaq: ALEC and GlaxoSmithKline plc LSENYSE: GSK, today announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies AL001 and AL101 designed to elevate progranulin PGRN levels. PGRN is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new immuno-neurology treatments. 